An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

Launched by ABBVIE · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the long-term use and effectiveness of a medication called risankizumab for adults with psoriatic arthritis (PsA), a condition that causes joint pain and swelling, often alongside skin issues like psoriasis. The trial will take place in about 15 countries outside the United States, involving 900 to 1,200 participants. Participants will either receive risankizumab or other advanced treatments for PsA, and the study will last for 24 months, following participants as they receive their usual care.

To be eligible for the trial, participants must have been diagnosed with psoriatic arthritis for at least six months and have not responded well to at least one other arthritis medication. Additionally, they should have active symptoms that meet specific criteria. Importantly, there won’t be any extra visits or tests beyond what patients usually have in their routine care. This study aims to help understand how well risankizumab works compared to other treatments in everyday clinical settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease.
• • Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.
• Exclusion Criteria:
• • - Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).